Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma.
Mitchell JS et al. Sci Rep. 2015 Jul 24;5:12473. doi: 10.1038/srep12473.

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.
Lazareth A et al. Haematologica. 2015 Jul 23. pii: haematol.2015.127001. [Epub ahead of print].

Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells.
Fink EE et al. Leukemia. 2015 Jul 24. doi: 10.1038/leu.2015.190. [Epub ahead of print].

Inhibitory effect of epirubicin-loaded lipid microbubbles with conjugated anti-ABCG2 antibody combined with therapeutic ultrasound on multiple myeloma cancer stem cells.
Shi F et al. J Drug Target. 2015 Jul 23:1-13. [Epub ahead of print].

Adoptive B-cell transfer mouse model of human myeloma.
Tompkins VS et al. Leukemia. 2015 Jul 23. doi: 10.1038/leu.2015.197. [Epub ahead of print].

Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.
Ziv E et al. Nat Commun. 2015 Jul 22;6:7539. doi: 10.1038/ncomms8539.

Esters of Bendamustine Are by Far More Potent Cytotoxic Agents than the Parent Compound against Human Sarcoma and Carcinoma Cells.
Huber S et al. PLoS One. 2015 Jul 21;10(7):e0133743. doi: 10.1371/journal.pone.0133743. eCollection 2015.

MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
Xie Z et al. Leukemia. 2015 Jun 30. doi: 10.1038/leu.2015.169. [Epub ahead of print].

Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.
Mrozik KM et al. Br J Haematol. 2015 Jul 20. doi: 10.1111/bjh.13596. [Epub ahead of print].

The 3′ to 5′ Exoribonuclease DIS3: From Structure and Mechanisms to Biological Functions and Role in Human Disease.
Robinson SR et al. Biomolecules. 2015 Jul 17;5(3):1515-39. doi: 10.3390/biom5031515.

RNA interference for multiple myeloma therapy: targeting signal transduction pathways.
Guo J et al. Expert Opin Ther Targets. 2015 Jul 20:1-15. [Epub ahead of print].

CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.
Roccaro AM et al. Cell Rep. 2015 Jul 15. pii: S2211-1247(15)00685-3. doi: 10.1016/j.celrep.2015.06.059. [Epub ahead of print].

Targeting the Pim kinases in multiple myeloma.
Keane NA et al. Blood Cancer J. 2015 Jul 17;5:e325. doi: 10.1038/bcj.2015.46.

Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T cell killing.
Leone P et al. Blood. 2015 Jul 16. pii: blood-2015-01-623975. [Epub ahead of print].

Transcription factor IKZF1 is degraded during the apoptosis of multiple myeloma cells induced by kinase inhibition.
Liu Y et al. FEBS Lett. 2015 Jul 13. pii: S0014-5793(15)00581-5. doi: 10.1016/j.febslet.2015.06.044. [Epub ahead of print].

Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma.
Bailey CK et al. Cancer Biol Ther. 2015 Jul 15:0. [Epub ahead of print].

BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics.
Touzeau C et al. Leukemia. 2015 Jul 15. doi: 10.1038/leu.2015.184. [Epub ahead of print].

Interrelationship between angiogenesis, inflammation and oxidative stress in Indian patients with multiple myeloma.
Joshi S et al. Clin Transl Oncol. 2015 Jul 14. [Epub ahead of print].

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.
Bi C et al. Oncotarget. 2015 Jul 3. [Epub ahead of print].

Logic-based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.
Chudasama VL et al. J Pharmacol Exp Ther. 2015 Jul 10. pii: jpet.115.224766. [Epub ahead of print].

FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
Wang Z et al. Cell Death Dis. 2015 Jul 9;6:e1815. doi: 10.1038/cddis.2015.187.

NEDD8 inhibition overcomes CKS1B induced drug resistance by upregulation of p21 in multiple myeloma.
Huang J et al. Clin Cancer Res. 2015 Jul 8. pii: clincanres.0254.2015. [Epub ahead of print].

NF-κB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity.
Ochodnicka-Mackovicova K et al. Blood. 2015 Jul 7. pii: blood-2015-01-621623. [Epub ahead of print].

Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort.
Møller HE et al. APMIS. 2015 Aug;123(8):652-8. doi: 10.1111/apm.12411. Epub 2015 Jul 8.

Dysregulation of the NLRP3 inflammasome complex and related cytokines in patients with multiple myeloma.
Li Y et al. Hematology. 2015 Jul 6. [Epub ahead of print].

Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Gupta N et al. Cancer Chemother Pharmacol. 2015 Jul 4. [Epub ahead of print].

The antigenic landscape of multiple myeloma: mass spectrometry (re-)defines targets for T-cell based immunotherapy.
Walz S et al. Blood. 2015 Jul 2. pii: blood-2015-04-640532. [Epub ahead of print].

Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma.
Rosko A et al. Bone Marrow Transplant. 2015 Jun 29. doi: 10.1038/bmt.2015.143. [Epub ahead of print].

A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E et al. Autophagy. 2015 Jul 3;11(7):1161-78. doi: 10.1080/15548627.2015.1052928.

Evaluation of Pharmacokinetic and Pharmacodynamic Interactions when Lenalidomide is Co-administered with Warfarin in a Randomized Clinical Trial Setting.
Weiss D et al. Clin Drug Investig. 2015 Jul;35(7):455-61. doi: 10.1007/s40261-015-0299-1.

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.
Yousef S et al. Hum Vaccin Immunother. 2015 Jul 3;11(7):1606-11. doi: 10.1080/21645515.2015.1046658.

Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.
Tian E et al. Genes Chromosomes Cancer. 2015 Jul 29. doi: 10.1002/gcc.22280. [Epub ahead of print].

Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma.
Faridvand Y et al. Redox Rep. 2015 Jul 28. [Epub ahead of print].